Management
Dr. Jean-Paul Kress
Chief Executive Officer
Biography Dr. Jean-Paul Kress
Chief Executive Officer
| Year of Birth | 1965 |
| Nationality | French |
| Management Board Member of MorphoSys AG since | 2019 |
| End of appointment | 2021 |
Dr. Jean-Paul Kress joined MorphoSys in September 2019. Prior to joining MorphoSys, he served as President and Chief Executive Officer of Syntimmune (now Alexion). Dr. Kress brings over 20 years of experience in the pharmaceutical and biotechnology industry, with a strong track record of commercial, operational and business development leadership in various senior management roles in North America and Europe. Among other assignments, he acted as Executive Vice President and Head of Global Therapeutic Operations at Biogen and Senior Vice President, Head of North America at Sanofi Genzyme. Previously, he was Chief Executive Officer of Sanofi Pasteur MSD, and gained further experience in positions at Gilead, Abbvie and Eli Lilly.
Dr. Kress received an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in pharmacology and immunology from École normale supérieure in Paris.
MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES
| Erytech Pharma SA, Lyon, France (publicly listed Company) | Member of the Board of Directors |
As of September 2019
Jens Holstein
Chief Financial Officer
Biography Jens Holstein
Chief Financial Officer
| Year of Birth | 1963 |
| Nationality | German |
| Management Board Member of MorphoSys AG since | 2011 |
| End of appointment | 2020 |
Jens Holstein joined MorphoSys from Fresenius Kabi AG, where he most recently served as Regional CFO for the region EME (Europe/Middle East) and as Managing Director of Fresenius Kabi Deutschland GmbH. Over the last almost 16 years at Fresenius he had held a variety of financial and general management positions. From 2006 to 2010, he was Regional Chief Financial Officer of Fresenius Kabi Asia Pacific Ltd., based in Hong Kong. Prior to this appointment, Mr. Holstein was Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company's subsidiary Wittgensteiner Kliniken AG. Earlier positions within Fresenius included General Manager of hospitalia care GmbH, Commercial Manager of the Projects & Service business unit of Fresenius AG and Commercial Manager of hospitalia international GmbH. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry, with positions in Frankfurt and London.
Mr. Holstein holds a Diploma in Business Administration from University of Münster.
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
| InflaRx N.V., Jena, Germany (publicly listed company) | Member of the Board of Directors |
As of January 2019
Dr. Malte Peters
Chief Development Officer
Biography Dr. Malte Peters
Chief Development Officer
| Year of Birth | 1962 |
| Nationality | German |
| Management Board Member of MorphoSys AG since | 2017 |
| End of appointment | 2022 |
Dr. Peters joined MorphoSys from Sandoz International, Holzkirchen, Germany, where he was Global Head of Clinical Development of the Biopharmaceuticals Business Unit. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.
Dr. Peters received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany. After scientific work at different universities he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
| Tango Therapeutics, Cambridge, MA, U.S. (not publicly listed company; group mandate) | Member of the Board of Directors |
As of January 2019
Dr. Markus Enzelberger
Chief Scientific Officer
Biography Dr. Markus Enzelberger
Chief Scientific Officer
| Year of Birth | 1969 |
| Nationality | Deutsch |
| Management Board Member of MorphoSys AG since | 2017 |
| End of appointment | 2020 |
Dr. Enzelberger joined MorphoSys in 2002 and served in different leadership positions within R&D. Since 2012 he acted as Senior Vice President Discovery, Alliances and Technologies, taking responsibility for discovery programs for MorphoSys’s partners and MorphoSys’s proprietary pipeline as well as for the technology development. Dr. Enzelberger is co-inventor of the HuCAL Platinum and the Ylanthia libraries and worked on Guselkumab and many other programs within MorphoSys’s pipeline. His new areas of responsibility include discovery, technology development, protein sciences, manufacturing and alliance management.
Before joining MorphoSys, Dr. Enzelberger did his postdoc with Steven Quake at the California Institute of Technology on microfluidic biological assays, where he co-invented the key technologies of Fluidigm (South San Francisco, CA, USA).
Dr. Enzelberger studied Chemistry and was awarded a Doctor of Natural Sciences by the Technical University of Stuttgart, Germany. He performed his Diploma thesis together with Bayer and his PhD thesis with BASF on the use of enzymes in chemical processes.
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
| SHS Gesellschaft für Beteiligungsmanagement mbH, Tuebingen, Germany (not publicly listed company; group mandate) |
Member of the Advisory Board |
As of January 2019
Dr. Marc Cluzel
Chairman
Biography and additional memberships Dr. Marc Cluzel
Chairman
| Year of birth | 1955 |
| Nationality | French |
| Place of residence | Montpellier, France |
| Initial Appointment | 2012 |
| End of Period | 2021 |
Professional Development
| Currently |
Member of the Supervisory Board of MorphoSys AG as well as member of comparable foreign supervisory board of a commercial enterprise (see below) |
|
2011 – 2012 |
Executive Vice President of Product Development, HÙYÀ Bioscience International, LLC, San Diego, CA, USA |
| 2009 - 2010 |
Executive Vice President of Research & Development, Sanofi-Aventis S.A., Paris, France |
| 2007 – 2009 |
Senior Vice President of Science and Medical Affairs, Sanofi-Aventis S.A., Paris, France |
| 2002 – 2011 |
Chairman and CEO, Sanofi-Aventis R&D France, Paris, France |
| 1996 – 2001 |
Head of Project Direction, Sanofi R&D France, Paris, France |
| 1993 – 1996 |
Project Director, Sanofi R&D France, Paris, France |
|
1991 – 1993 |
Clinical Pharmacologist, Sanofi R&D France, Montpellier, France |
Education
| 1983 – 1990 | Ph.D. Biochemistry at University of Montpellier, France |
| 1973 – 1985 | M.D., Study of Medicine at University of Montpellier, France |
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
| Moleac Pte. Ltd., Singapore* | Member of the Board of Directors |
| Griffon Pharmaceuticals Inc., Montreal Canada* | Member of the Board of Directors |
*not publicly listed company; group mandate
As of January 2020
Dr. Frank Morich
Deputy Chairman
Biography and additional memberships Dr. Frank Morich
Deputy Chairman
| Year of birth | 1953 |
| Nationality | German |
| Place of residence | Berlin, Germany |
| Initial Appointment | 2015 |
| End of Period | 2020 |
Professional Development
| Currently |
Self-employed business consultant in the life science and healthcare industries |
| 2011 - 2014 | Chief Commercial Officer and Member of the Board of Directors, Takeda Pharmaceutical Company Ltd., Tokyo, Japan, as well as CEO, Takeda Pharmaceutical International GmbH, Glattbrugg, Switzerland |
| 2010 – 2011 | Executive Vice President International Operations, Takeda Pharmaceutical International, Inc., Deerfield, IL, USA |
| 2008 – 2010 | CEO, NOXXON Pharma AG, Berlin, Germany |
| 2005 – 2007 | CEO and Member of the Board of Directors, Innogenetics N.V., Ghent, Belgium |
| 2004 | CEO and Chairman of the Executive Board, AM-Pharma B.V., Utrecht, The Netherlands |
| 2003 – 2004 | Independent consultant for the venture capital, life sciences and health care industries |
| 2002 | Chairman of the Board of Management and Chairman of the Executive Committee, Bayer HealthCare AG, Leverkusen, Germany |
| 2000 – 2002 | Member of the Board of Management, Bayer AG, Leverkusen, Germany |
| 1993 – 2000 | General Manager Consumer Care Division, Head of Global Product Development and Head of Research and Development, Bayer AG, Leverkusen, Germany |
| 1991 – 1993 | Director Clinical Research (CNS), Miles Inc., West Haven, CT, USA |
| 1982 – 1991 | Head of Institute of Biochemistry, Head of Institute of Pharmacology, Laboratory Head/Head of Cellular/In-Vitro Research, Institute of Pharmacology, Bayer AG, Wuppertal, Germany |
| 1979 - 1980 | Staff Physician, German Army, Marburg, Germany |
Education
| 1992 |
“Managing for Global Success” Executive Development Program, Columbia University, NY, USA |
| 1980 – 1982 | Postdoctoral Fellow, Institute of Experimental Immunology, University of Marburg, Germany |
| 1979 | Dissertation & MD degree as physician and registered to practice medicine |
| 1972 – 1979 | Medical studies at the University of Marburg, Germany |
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
| Cue Biopharma Inc., Cambridge, MA, USA (publicly listed company) | Member of the Board of Directors |
As of Januar 2020
Wendy Johnson
Member
Biography and additional memberships Wendy Johnson
Member
| Year of birth | 1952 |
| Nationality | US-American |
| Place of residence | San Diego, CA, USA |
| Initial Appointment | 2015 |
| End of Period | 2020 |
Professional Development
| Currently |
Chief Operating Officer, Reneo Pharmaceuticals, San Diego, CA, USA; |
| 2007 – 2014 | Founder, President and CEO, Aires Pharmaceuticals, Inc., San Diego, CA, USA |
| 2005 – 2014 | Venture Partner, ProQuest Investments, San Diego, CA, USA |
| 2001 – 2005 | Senior Vice President Corporate Development, Salmedix, Inc., San Diego, CA, USA |
| 2000 – 2001 | Independent Consultant, San Diego, CA, USA |
| 2000 – 1998 |
Vice President Business Development, Women First HealthCare, San Diego, CA, USA |
| 1998 – 1994 | Vice President Corporate Development & Operations, Selective Genetics, San Diego, CA, USA |
| 1994 – 1990 | Vice President Business Development & Regulatory Affairs, Cytel Corp., San Diego, CA, USA |
| 1990 – 1988 | Manager Business Development, Synbiotics Corp., San Diego, CA, USA |
| 1988 – 1986 | International Business Development & Regulatory Affairs Manager, Murex Corp., Cambridge, Great Britain |
| 1986 – 1976 | Assistant Director, US Food & Drug Administration, Center for Devices & Radiological Health, Rockville, MD, USA |
Education
| 1986 – 1984 |
M.B.A., Loyola Marymount University, Los Angeles, CA, USA |
| 1976 – 1974 | M.S. Clinical Microbiology, Hahnemann University Hospital, Philadelphia, PA, USA |
| 1974 – 1970 | B.S. Microbiology, University of Maryland, College Park, MD, USA |
No Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
As of January 2020
Krisja Vermeylen
Member
Biography and additional memberships Krisja Vermeylen
Member
| Year of birth | 1962 |
| Nationality | Belgian |
| Place of residence | Herentals, Belgium |
| Initial Appointment | 2017 |
| End of Period | 2021 |
Professional Development
| Currently | Self-employed business consultant in the life science and healthcare industries |
| 2015 - 2018 | Senior Vice President Corporate People & Organisation, Novo Nordisk A/S, Bagsvaerd, Denmark |
| 2013 – 2015 |
Corporate Vice President and General Manager (CVP), Novo Nordisk Pharma GmbH, Mainz, Germany |
| 2008 – 2013 |
Vice President (France & BeLux), Novo Nordisk SA, Paris, France |
| 2002 – 2013 |
Vice President Europe West (France, Belgium, Luxembourg, Netherlands), Novo Nordisk SA, Paris, France |
| 1998 – 2002 |
General Manager (BeLux & Director GHT France), Novo Nordisk SA, Brussels, Belgium |
| 1997 – 1998 |
Marketing & Sales Manager Diabetes/Women Health Care/Growth Hormone/Haemophilia, Novo Nordisk SA, Brussels, Belgium |
| 1997 |
Marketing Manager Diabetes/Women Health Care/Growth Hormone, Novo Nordisk SA, Brussels, Belgium |
| 1996 – 1997 |
Senior Product Manager Anaesthesia and Cardiovascular, Pharmacia & Upjohn, Brussels, Belgium |
| 1995 | Product & Sales Manager Low molecular weight heparin, Pharmacia, Brussels, Belgium |
| 1994 – 1995 | Product Manager Anaesthesia and Cardiovascular, Pharmacia, Brussels, Belgium |
| 1993 – 1994 | Product Manager Anaesthesia, Pharmacia, Brussels, Belgium |
| 1991 – 1993 | Medical Representative Hospital Division Parenteral Nutrition, Kabi Pharmacia, Brussels, Belgium |
| 1986 – 1991 | Pharmacist dispenser |
Education
| 2015 - 2017 | Independent Director Program (IDP) INSEAD France |
| 2002 | Advanced Management Program (AMP) INSEAD France |
| 1985 – 1986 | Doctoral student of bromatology at the University of Antwerp (UIA), Antwerp, Belgium |
| 1980 – 1985 | Pharmacist / Master in pharmaceutical sciences at the University of Antwerp (UIA, RUCA), Antwerp, Belgium |
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
| Spencer Stuart Belgien* | Member of the Advisory Board |
*not publicly listed company; group mandate
As of January 2020
Dr. George Golumbeski
Member
Biography and additional memberships Dr. George Golumbeski
Member
| Year of birth | 1957 |
| Nationality | US-American |
| Place of residence | Far Hills, NJ, USA |
| Initial Appointment | 2018 |
| End of Period | 2020 |
Professional Development
|
Since 2018 |
Self-employed business consultant in the life science and healthcare industries |
|
2018 - 2019 |
President, Grail Inc., Menlo Park, CA, USA (as of August 1, 2018) |
|
2017 – 2018 |
Executive Vice President & Executive Advisor for Innovation, Celgene Corporation, Summit, NJ, USA (until April 16, 2018) |
|
2009 – 2017 |
Executive Vice President, Business Development, Celgene Corporation, Summit, NJ, USA |
|
2008 – 2009 |
Chief Executive Officer, Nabriva Therapeutics AG, Vienna, Austria |
|
2002 – 2008 |
Vice President, Business Development, Lincensing & Strategy, Novartis Oncology, Florham Park, NJ, USA |
|
2001 – 2002 |
Vice President, R&D Business Development, Elan Biopharmaceuticals, San Diego, CA, USA |
|
2000 – 2001 |
Senior Director, Licensing, EMD Pharmaceuticals, Durham, NC, USA |
|
1997 – 2000 |
Vice President / Director, Corporate Development, Schwarz Pharma, Mequon, WI, USA |
|
1996 – 1997 |
Director, Business Development, Pierce Chemical Company, Rockford, IL, USA |
|
1991 – 1995 |
Technology Acquisition Manager / Group Leader, Research & Development / Group Leader, Diagnostics Research & Development, Promega Corporation, Madison, WI, USA |
Education
| 1985 | Ph.D., Genetics, University of Wisconsin-Madison, Madison, WI, USA |
| 1986 – 1991 | Postdoctoral Research, Molecular biology, University of Colorado Boulder, Boulder, CO, USA |
| 1997 | B.A., Biology, University of Virginia, Charlottesville, VA, USA |
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
| Aura Biosciences Inc., Cambridge, MA, USA* | Chairman of the Board of Directors |
| Carrick Therapeutics Ltd., Dublin, Ireland* | Chairman of the Board of Directors |
| Enanta Pharmaceuticals, Inc., Watertown, MA, USA (publicly listed company) |
Member of the Board of Directors |
| KSQ Therapeutics, Inc., Cambridge, MA, USA* | Member of the Board of Directors |
| Sage Therapeutics, Cambridge, MA, USA (publicly listed company) | Member of the Board of Directors |
| Shattuck Labs, Inc., Austin, TX, USA* | Member of the Board of Directors |
| Verseau Therapeutics, Bedford, MA, USA* | Chairman of the Board of Directors |
* not publicly listed company; group mandate
As of January 2020
Michael Brosnan
Member
Biography and additional memberships Michael Brosnan
Member
| Year of birth | 1955 |
| Nationality | US-American |
| Place of residence | Westford, MA, USA |
| Initial Appointment | 2018 |
| End of Period | 2020 |
Professional development
| Since 2010 | Chief Financial Officer, Fresenius Medical Care Management AG, Bad Homburg v.d.H, Germany |
| 2003 – 2009 | Executive Vice President and Chief Financial Officer, Fresenius Medical Care North America, Waltham, MA, USA |
| 1999 – 2003 | Senior Vice President of Finance, Fresenius Medical Care North America, Waltham, MA, USA |
| 1998 | Vice President Finance and Administration, Spectra Renal Management, Waltham, MA, USA |
| 1997 | Vice President of Financial Operations, High Voltage Engineering Corporation, Wakefield, MA, USA |
| 1994 – 1996 | Senior Controller, Commercial Imaging Group, Polaroid Corporation, Cambridge, MA, USA |
| 1978 – 1993 | KPMG, Boston, MA, USA, (1988 – 1993 Audit Partner) |
Education
| 1978 | BSc, Business Administration, Accounting, Northeastern University, Boston, MA, USA |
Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises
| Fresenius Medical Care Holdings, Inc., U.S.*, Waltham, MA, USA | Member of the Board of Directors |
| Vifor Fresenius Medical Care Renal Pharma Ltd., CH* Glattbrugg, Switzerland | Member of the Board of Administration |
*not publicly listed company; group mandate
As of April 2019
Sharon Curran
Member
Biography and additional memberships Sharon Curran
Member
|
Year of birth |
1968 |
|
Nationality |
Irish |
|
Place of residence |
Dublin, Ireland |
|
Initial Appointment |
2019 |
|
End of Period |
2021 |
PROFESSIONAL DEVELOPMENT
|
Currently |
Non-Executive Director in life sciences and healthcare industries |
|
2014 – 2017 |
Vice President, Global Specialty Franchise & Customer Excellence, AbbVie, Chicago, IL, USA |
|
2012 – 2014 |
Vice President and Senior Director, Global Marketing Specialty, Global Marketing & Commercial Operations, AbbVie, Chicago, IL, USA |
|
2009 – 2012 |
Global Brand & Commercial Director, Abbott International Office, Ireland |
|
2002 – 2008 |
Divisional Head, Strategy & Operations, Eli Lilly, UK & Ireland |
|
1999 – 2002 |
Divisional Head, Primary Care Strategy & Operations, Eli Lilly, UK |
|
1996 – 1999 |
Group Marketing/Business Unit Manager, Eli Lilly, Dublin, Ireland |
|
1995 - 1996 |
Hospital Sales Specialist, Eli Lilly, Dublin, Ireland |
|
1993 – 1995 |
Hospital Sales Representative, Novo Nordisk, Dublin, Ireland |
|
1992 – 1993 |
Medical Device Sales Representative, Dublin, Ireland |
EDUCATION
|
2007 - 2008 |
MSc Business Administration, Trinity College Dublin, Ireland |
|
1989 -1992 |
BSc Biotechnology, Dublin City University, Ireland |
|
1986 – 1989 |
Associate of Institute of Medical Laboratory Science, DIT/ Technological University, Dublin, Ireland |
MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES
|
Circassia Pharmaceuticals plc., Oxford, United Kingdom (publicly listed company) |
Member of the Board of Directors |
As of January 2020
Composition of the Supervisory Board Since Termination of the 2019 Annual General Meeting
| Initial Appointment |
End of Period |
Audit Committee |
Remuneration and Nomination Committee |
Science and Technology Committee |
|
|---|---|---|---|---|---|
| Dr. Marc Cluzel | 2012 | 2021 | M | ||
| Dr. Frank Morich | 2015 | 2020 | M | M | |
| Krisja Vermeylen | 2017 | 2021 | M | C | |
| Wendy Johnson | 2015 | 2020 | M | ||
| Dr. George Golumbeski | 2018 | 2020 | C | ||
| Michael Brosnan (FE) | 2018 | 2020 | C | ||
| Sharron Curran | 2019 | 2021 | M | ||
FE=Independent Financial Expert C=Chairperson M=Member
Composition of the Supervisory Board until Termination of the 2019 Annual General Meeting
| Initial Appointment |
End of Period |
Audit Committee |
Remuneration and Nomination Committee |
Science and Technology Committee |
|
|---|---|---|---|---|---|
| Dr. Marc Cluzel | 2012 | 2021 | M | ||
| Dr. Frank Morich | 2015 | 2020 | M | M | |
| Krisja Vermeylen | 2017 | 2019 | M | C | |
| Wendy Johnson | 2015 | 2020 | M | M | |
| Dr. George Golumbeski | 2018 | 2020 | C | ||
| Michael Brosnan (FE) | 2018 | 2020 | C | ||
FE=Independent Financial Expert C=Chairperson M=Member